EUCTR2009-011739-11-DE进行中（未招募）不适用
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squamous, Non-Small Cell Lung Cancer - A Study in Patients with Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Histologic or cytologic diagnosis of unresectable nonsquamous Stage IIIA or Stage IIIB NSCLC. Squamous cell and/or mixed small cell, non-small cell histology is not permitted.
- •[2]Have an ECOG PS of 0 or 1.
- •[3]Previous radiation therapy is allowed, but should have been limited and must not have included thoracic radiation, whole pelvis radiation, or radiation to >25% of the patient’s bone marrow. Patients must have recovered from the toxic effects of radiation treatment prior to study enrollment. Prior radiotherapy must be completed 30 days before study entry.
- •[4]Have at least 1 unidimensionally measurable lesion meeting RECIST guidelines, version 1.0. Positron emission tomography (PET) scans and ultrasounds may not be used.
- •[5]Estimated life expectancy of at least 12 weeks.
- •[6]Patient compliance and geographic proximity that allow adequate follow-up.
- •[7]Adequate organ function, including the following:
- •Adequate bone marrow reserve, adequate hepatic, pulmonary and renal functions.
- •[8]Patients must sign an ICD.
- •[9]Patients must be at least 18 years of age.
- •[10]Patients must have completed a 3-D plan, and the attending physician must have reviewed and approved the dose volume histograms with a total lung V20 < or = 35%.
- •[11]For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 6 months after the treatment period; must have a negative serum pregnancy test within 7 days before study enrollment and must not be breast-feeding.
- •For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.
- •[12] Have not received prior systemic anticancer therapy for NSCLC. No prior adjuvant chemotherapy is allowed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[13]Have received treatment within the last 30 days of enrollment with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[14]Have previously completed or withdrawn from this study or any other study investigating pemetrexed.
- •[15]Have a serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol.
- •[16]Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV.
- •[17]Have had a prior malignancy other than NSCLC, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence. Patients with a history of low-grade (Gleason score < or = 6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously.
- •[18]Are receiving concurrent administration of any other antitumor therapy.
- •[19]Have had weight loss > 10% over the previous 3 months before study entry.
- •[20]Are unable to interrupt aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose < or = 1.3 grams per day, for at least 2 days before (5 days for long-acting agents), the day of, and for at least 2 days after administration of pemetrexed.
- •[21]Are unable or unwilling to take folic acid or vitamin B12 supplementation.
- •[22]Are unable or unwilling to take corticosteroids.
- •[23]Have received a recent yellow fever vaccination (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination.
- •[24]Have known hypersensitivity to pemetrexed, cisplatin, or any of the excipients in these medicinal products.
- •[25]Have evidence of clinical hearing loss.
- •[26]Have clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
研究者
相似试验
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squamous, Non-Small Cell Lung Cancer - A Study in Patients with Non-Small Cell Lung Canceron-small Cell Lung CancerMedDRA version: 9.1Level: LLTClassification code 10029520Term: Non-small cell lung cancer stage IIIAMedDRA version: 9.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBEUCTR2009-011739-11-FREli Lilly and Company Limited90
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squamous, Non-Small Cell Lung Cancer - NDEUCTR2009-011739-11-ITEli Lilly and Company Limited88
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
进行中（未招募）
1 期
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-DEEli Lilly and Company125